Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer’s disease: a randomized trial

Abstract Intranasal insulin (INI) has shown promise as a treatment for Alzheimer’s disease (AD) in pilot clinical trials. In a recent phase 2 trial, participants with mild cognitive impairment (MCI) or AD who were treated with INI with one of two delivery devices showed improved cerebral spinal flui...

Full description

Bibliographic Details
Main Authors: Derek Kellar, Thomas Register, Samuel N. Lockhart, Paul Aisen, Rema Raman, Robert A. Rissman, James Brewer, Suzanne Craft
Format: Article
Language:English
Published: Nature Portfolio 2022-01-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-05165-3